Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Phase II, Phase I Treatment Closed Over 18 Other ERLANGEN-1490 EU-20232, NCT00053391

Objectives

1. Compare the efficacy of vaccination with autologous dendritic cells pulsed with tumor and influenza antigen peptides treated with vs without ex vivo CD40-ligand, in terms of tumor-specific T-cell response, in patients with HLA-A1 and/or HLA-A2.1 positive stage III or IV melanoma.
2. Determine the safety and tolerability of these vaccinations in these patients.
3. Determine tumor response and recurrence rates in patients treated with these vaccinations.

Entry Criteria

Disease Characteristics:

• Histologically confirmed stage III or IV cutaneous malignant melanoma



• HLA-A1 and/or HLA-A2 expression by serologic HLA typing
  • HLA-A2.1 subtype must be confirmed by polymerase chain reaction on genomic DNA obtained from peripheral blood mononuclear cells



• No active CNS metastases by CT scan or MRI

Prior/Concurrent Therapy:

Biologic therapy

• More than 4 weeks since prior immunotherapy
• No other concurrent immunotherapy

Chemotherapy

• More than 4 weeks since prior systemic chemotherapy (6 weeks for nitrosoureas)
• No concurrent chemotherapy

Endocrine therapy

• No concurrent corticosteroids

Radiotherapy

• More than 4 weeks since prior radiotherapy
• No prior radiotherapy to the spleen
• Concurrent palliative radiotherapy allowed

Surgery

• Recovered from prior surgery
• No prior splenectomy
• No prior organ allograft
• Concurrent surgery on selected metastases (e.g., because of pain or local complications such as compression) allowed

Other

• No other concurrent investigational drugs
• No concurrent participation in another clinical trial

Patient Characteristics:

Age

• Over 18

Performance status

• Karnofsky 60-100%

Life expectancy

• At least 4 months

Hematopoietic

• WBC greater than 2,500/mm³
• Neutrophil count greater than 1,000/mm³
• Lymphocyte count greater than 700/mm³
• Platelet count greater than 75,000/mm³
• Hemoglobin greater than 9 g/dL
• No bleeding disorders

Hepatic

• Bilirubin less than 2.0 mg/dL
• Hepatitis B surface antigen negative
• Hepatitis C antibody negative

Renal

• Creatinine less than 2.5 mg/dL

Cardiovascular

• No clinically significant heart disease

Pulmonary

• No clinically significant respiratory disease

Immunologic

• No active systemic infection
• No immunodeficiency disease
  • No evidence of HIV-1, HIV-2, or human T-cell lymphotropic virus-1
• No active autoimmune disease including (but not limited to):
  • Lupus erythematosus
  • Autoimmune thyroiditis or uveitis
  • Multiple sclerosis
  • Inflammatory bowel disease

Other

• Stable medical condition
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for at least 1 month after study participation
• No organic brain syndrome or psychiatric illness that would preclude study compliance
• No other concurrent active malignancy
• No other concurrent serious illness that would preclude study treatment
• No contraindication to leukapheresis

Expected Enrollment

A total of 8-30 patients will be accrued for this study within 6-12 months.

Outcomes

Comparison of the efficacy of vaccination with vs without ex vivo CD40-ligand in terms of tumor-specific T-cell response
Safety
Tolerability

Tumor response
Recurrence rates

Outline

This is an open-label non-randomized study.

• Phase I: Patients undergo leukapheresis for collection of peripheral blood mononuclear cells (PBMC). PBMC are cultured with sargramostim (GM-CSF) and interleukin-4 to generate dendritic cells (DCs) on day -9. DCs are pulsed separately with HLA-A1 and HLA-A2.1-restricted flu matrix peptides derived from melanoma-associated tumor antigens (MAGE-10.A2, Melan-A, MAGE-3, NY-ESO-1, gp100 antigen, and tyrosinase peptide). Half of the DCs are treated ex vivo with CD40-ligand. Patients receive the peptide-pulsed DC vaccinations subcutaneously (SC) on days 1, 14, 42, and 70 in the absence of disease progression.

  Patients who show tumor response (at least stable disease) at day 98 progress to phase II of the study.




• Phase II: Patients undergo leukapheresis as in phase I on days 102, 352, and 688. Patients receive up to 6 additional booster vaccinations SC as in phase I on days 126, 184, 268, 356, 520, and 692.

Patients are followed for 10 years.

Trial Contact Information

Trial Lead Organizations

Dermatologische Klinik mit Poliklinik - Universitaetsklinikum Erlangen

Gerold Schuler, Protocol chair		Ph: 49-9131-85-33164

Registry Information
Official Title		Vaccination Of HLA-A1 And/Or -A2+ Stage III or IV Melanoma Patients With Tumor Peptide - Loaded Autologous Dendritic Cells That Are Generated In The Absence Or Presence Of CD40 Ligand
Trial Start Date		2002-10-23
Registered in ClinicalTrials.gov		NCT00053391
Date Submitted to PDQ		2002-10-03
Information Last Verified		2006-08-15